Bad News For Newly Immunized Babies
High-tech synthetic antibodies have never been injected in a human on the first day of life before, so as one could expect, it is a brave new world for babies and the fate of this novel public health intervention.
Dr. Helene Banoun has summarized the clinical trials and the early post-marketing results with Beyfortus (nirsevimab) and the results are not good.
Despite theoretical reductions in RSV calculated from the studies, the observed cases of invasive RSV infection and death nearly immediately after the shot are alarmingly imbalanced with worsened outcomes for babies given Beyfortus.
Current Issues in Molecular Biology. 2024; 46(9):10369-10395. https://doi.org/10.3390/cimb46090617
Banoun believes the antibody may make RSV infection worse because of antibody dependent enhancement.
That means the antibody grabs the virus and human cells in turn can then attach to the end of the antibody and pull the virus into the cell making the infection worse.
Because half of babies get RSV in the first year of life and it is easily treated with nebulized medicine at home, nirsevimab for all appears to be a dangerous proposition.
Not only does the antibody worsen the infection in some victims, but it may globally lead to resistant strains of RSV making it a much bigger public health problem in a few years.
If a child is hospitalized with RSV, they can not only be managed oxygen, nebulizers, ribavirin, but also safer monoclonal antibodies (palivizumab) designed for acute use.
Banoun’s analysis suggest parents with healthy newborns should consider deferring on this new biotechnology and allowing the natural immune system to develop on its own.
See more here Substack
Please Donate Below To Support Our Ongoing Work To Defend The Scientific Method
PRINCIPIA SCIENTIFIC INTERNATI ONAL, legally registered in the UK as a company 
incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX.
Trackback from your site.